See C. Correa, “Protecting Test Data for Pharmaceutical and Agrochemical Products under Free Trade Agreements”, in Negotiating Health, pp. As mentioned before, however, it is widely recognized that this obligation creates insurmountable barriers for generic producers in terms of financial resources and time. Where the protected data concern off-patent substances, a data exclusivity regime therefore erects an important new market access barrier for generic producers.